Website in archive mode. Questions? Email [email protected]

  Vertex Pharmaceuticals Inc ( VRTX ) |
1996 - 2021 (26 years)

Net Revenue (Sales) is 
$6.6B (1Y +15.8% )

VRTX Stock Price & Net Revenue (Sales)

Net Revenue (Sales) for VRTX competitors.
GILD BMY JNJ MRK ABBV ENTA
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Net Revenue (Sales)

chevron_right 2021 $3.4B +309x
( +24.7% / year avg)
chevron_left 1996 $10.8M
vertical_align_top Peak $6.0B +553x
vertical_align_bottom Bottom $10.8M
arrow_drop_up # Up Years 16 16 of 26
years up.
arrow_drop_down # Down Years 10
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • VRTX's stock price has rallied +5,830% from $4.5 in 1996 , or +0.19x the rate relative to it's net revenue (sales) over the same period.
  • If VRTX grows it's stock at the same rate as it's net revenue (sales) (+24.7%/year) , it's stock price will grow +909% and hit $2426.23 over the next 10 years.
  • VRTX's stock price has gone up 11 of the 16 years (+68%) it's net revenue (sales) were also up.
5-Year Change 🚀
+333%$6.9BNet Revenue (Sales)
+279%$769.3MCost of Revenue (Sales)
+340%$6.1BGross Profit Margin
+1.8%3.55Gross Profit Margin Ratio
+78.2%$1.8BResearch and Development (R&D)
+82.6%$768.3MSelling, General, and Administrative (SG&A)
-1,293.7%-$210.6MOther Income/Expenses, Net
+79.5%$2.6BTotal Operating Expenses
+103%$3.3BCost & Expenses
-24.3%$62.7MInterest Expense/Income, Net
+75.7%$115.3MDepreciation & Amortization (D&A)
-6,607.6%$3.6BOperating Income
-2,781.4%$3.3BPretax Income (Earnings)
-719.0%1.9Pretax Income (Earnings) Margin
+2,959%$671.3MProvision For Income Taxes
-1,668.9%$2.6BNet Income (Earnings)
-1,575.5%10.03Earnings Per Share (EPS)
-1,554.9%9.89Earnings Per Share (EPS) Diluted
+6.79%$1.0BShares Outstanding
+8.3%$1.1BShares Outstanding (Diluted)
  • Line Item (in $M) FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998 FY 1997
    1 Revenue 6205683000 4162821000 3047597000 2488652000 1702177000 1032336000 580415000 1211975000 1527042000 1410626000 143370000 101889000 175504000 199012000 216356000 160890000 102717000 69141000 161085000 167490000 78127000 61600000 44400000 43800000
    2 Cost of Revenue 736300000.00 547758000.00 409539000.00 275119000.00 210460000.00 124512000.00 60987000.00 130277000.00 279885000.00 80505000.00 12730000.00 14202000.00 15686000.00 13904000.00 12170000.00 10098000.00 5649000.00 3126000.00 28281000.00 39629000.00 4082000.00 -3400000.00 -4500000.00 -3600000.00
    3 Gross Profit (Income) 5469383000 3615063000 2638058000 2213533000 1491717000 907824000 519428000 1081698000 1247157000 1330121000 130640000 87687000 159818000 185108000 204186000 150792000 97068000 66015000 132804000 127861000 74045000 65000000 48900000 47400000
    4 R&D 1829537000 1754540000 1416476000 1324625000 1047690000 995922000 855506000 918783000 806185000 707706000 637416000 550274000 516292000 513054000 371713000 248540000 192162000 199636000 203018000 148673000 84921000 72200000 58700000 51600000
    5 SG&A 770456000.00 658498000.00 557616000.00 496079000.00 432829000.00 376575000.00 305409000.00 362342000.00 436796000.00 400721000.00 187800000.00 130192000.00 101910000.00 84727000.00 57860000.00 43990000.00 42139000.00 39082000.00 49390000.00 47337000.00 27806000.00 26100000.00 18100000.00 11400000.00
    6 Other Expenses 296420000.00 192177000.00 -790000.00 -81382000.00 4130000.00 -6715000.00 30400000.00 -49939000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    7 Operating Expenses 2599993000 2413038000 1974092000 1820704000 1480519000 1372497000 1160915000 1281125000 1242981000 1108427000 825216000 680466000 618202000 597781000 429573000 292530000 234301000 238718000 252408000 196010000 112727000 104600000 81300000 66600000
    8 Interest Expense 58151000.00 58502000.00 34119000.00 57550000.00 81432000.00 84206000.00 72863000.00 22730000.00 16653000.00 38452000.00 19275000.00 13192000.00 13471000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    9 D&A 109515000.00 106941000.00 72420000.00 61397000.00 61398000.00 62343000.00 63257000.00 48365000.00 38191000.00 35041000.00 30459000.00 30107000.00 32196000.00 27459000.00 25868000.00 27289000.00 29640000.00 23438000.00 25432000.00 17964000.00 9095000.00 6300000.00 4500000.00 3600000.00
    10 EBITDA 2965805000 1308966000 736386000 454226000 72596000 -402330000 -578230000 -151062000 42367000 256735000 -664117000 -562672000 -426188000 -385214000 -199519000 -114449000 -107593000 -149265000 -94172000 -50185000 -29587000 -33300000 -27900000 -15600000
    11 Operating Income 2856290000.00 1202025000.00 663966000.00 392829000.00 11198000.00 -464673000.00 -641487000.00 -199427000.00 4176000.00 221694000.00 -694576000.00 -592779000.00 -458384000.00 -412673000.00 -225387000.00 -141738000.00 -137233000.00 -172703000.00 -119604000.00 -68149000.00 -38682000.00 -39600000.00 -32400000.00 -19200000.00
    12 Other Income Expenses (Net) 296420000.00 187718000.00 -29606000.00 -350968000.00 2868000.00 -8921000.00 -20525000.00 -753960000.00 -1844000.00 -124675000.00 -42730000.00 -41217000.00 -4324000.00 -7119000.00 2381000.00 -23518000.00 -3698000.00 -82822000.00 -55000.00 -26087000.00 -14925000.00 -700000.00 0.00 0.00
    13 Pre-Income Tax 3116798000.00 1394919000.00 600241000.00 -15689000.00 -67366000.00 -557800000.00 -734875000.00 -976117000.00 -12381000.00 60445000.00 -754626000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    14 Income Tax Expense 405151000.00 218109000.00 -1486862000.00 -107324000.00 16665000.00 30381000.00 6958000.00 -288567000.00 38754000.00 19266000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    15 Net Income 2711647000 1176810000 2096896000 263484000 -112052000 -556334000 -738555000 -445028000 -107032000 29574000 -754626000 -642178000 -459851000 -391279000 -206891000 -203417000 -166247000 -196767000 -108621000 -66233000 -39658000 -41000000 -33100000 -19800000
    16 EPS 10.44 4.58 8.24 1.06 -0.46 -2.31 -3.14 -1.98 -0.50 0.14 -3.77 -3.70 -3.27 -3.03 -1.83 -2.28 -2.12 -2.56 -1.43 -0.89 -0.73 -0.81 -0.66 -0.41
    17 EPS Diluted 10.29 4.51 8.09 1.04 -0.46 -2.31 -3.14 -1.98 -0.50 0.14 -3.77 -3.70 -3.27 -3.03 -1.83 -2.28 -2.12 -2.56 -1.43 -0.89 -0.73 -0.81 -0.66 -0.41
    18 Shares Outstanding 259841000 256728000 254292000 248858000 244685000 241312000 235307000 224906000 211946000 204891000 200402000 173259000 140556000 128986000 113221000 89241000 78571000 77004000 75749000 74464000 54322000 51036000 50598000 48528000
    19 Shares Outstanding (Diluted) 263396000 260673000 259185000 253225000 244685000 241312000 235307000 224906000 211946000 208807000 200402000 173259000 140556000 128986000 113221000 89241000 78571000 77004000 75749000 74464000 54322000 51036000 50598000 48528000
  • Line Item (in $M) FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998 FY 1997
    1 Cash & Cash Equivalents 5988187000 3109322000 2650134000 1665412000 1183945000 714768000 625259000 569299000 489407000 475320000 243197000 446658000 389115000 355663000 213171000 78045000 55006000 98159000 108098000 189205000 322090000 31500000 24200000 71500000
    2 Short Term Investments 670710000.00 698972000.00 518108000.00 423254000.00 250612000.00 327694000.00 761847000.00 895777000.00 831808000.00 493602000.00 788214000.00 838255000.00 442986000.00 105208000.00 491455000.00 283112000.00 337314000.00 485005000.00 526886000.00 553997000.00 66509000.00 0.00 0.00 0.00
    3 Cash & S-T Investments 6658897000 3808294000 3168242000 2088666000 1434557000 1042462000 1387106000 1465076000 1321215000 968922000 1031411000 1284913000 832101000 460871000 704626000 361157000 392320000 583164000 634984000 743202000 388599000 31500000 24200000 71500000
    4 Accounts Receivables 885352000.00 633518000.00 476462000.00 384503000.00 204296000.00 189290000.00 90057000.00 85517000.00 143250000.00 183135000.00 12529000.00 9601000.00 23489000.00 31320000.00 62923000.00 20595000.00 11891000.00 7324000.00 13200000.00 20265000.00 12262000.00 5900000.00 0.00 0.00
    5 Inventory 280777000.00 167502000.00 124360000.00 111830000.00 77604000.00 57207000.00 30848000.00 14147000.00 30464000.00 112430000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    6 Other Current Assets 308353000.00 0.00 0.00 0.00 16780000.00 12065000.00 7002000.00 23836000.00 24673000.00 983811000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4039000.00 5989000.00 2325000.00 157800000.00 224500000.00 210100000.00
    7 Total Current Assets 8133379000 4822829000 3843109000 2648963000 1831540000 1407153000 1546511000 1588576000 1589585000 1331254000 1057039000 1307026000 867581000 496851000 771406000 385055000 406712000 593806000 656572000 776092000 403186000 195200000 248700000 281600000
    8 PP&E 958534000.00 745080000.00 812005000.00 789437000.00 698362000.00 697715000.00 715812000.00 696911000.00 433609000.00 133176000.00 72333000.00 62279000.00 68331000.00 66509000.00 61535000.00 54533000.00 64225000.00 80083000.00 95991000.00 80377000.00 28149000.00 24500000.00 14500000.00 11100000.00
    9 Goodwill 1002158000.00 1002158000.00 50384000.00 50384000.00 50384000.00 50384000.00 39915000.00 30992000.00 30992000.00 30992000.00 26102000.00 26102000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    10 Intangible Assets 400000000.00 400000000.00 0.00 29000000.00 284340000.00 284340000.00 29000000.00 0.00 663500000.00 663500000.00 518700000.00 518700000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    11 Goodwill & Intangible Assets 1402158000.00 1402158000.00 50384000.00 79384000.00 334724000.00 334724000.00 68915000.00 30992000.00 694492000.00 694492000.00 544802000.00 544802000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    12 L-T Investments 670710000.00 0.00 0.00 20447000.00 20276000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7000000.00 57000000.00 65000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    13 Tax Assets 0.00 1190815000.00 1499672000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    14 Other Non-Current Assets 0.00 157583000.00 40728000.00 7783000.00 11885000.00 29283000.00 3441000.00 2562000.00 41602000.00 45358000.00 51272000.00 41381000.00 44567000.00 38117000.00 88638000.00 109410000.00 74516000.00 50522000.00 63157000.00 68662000.00 341546000.00 12700000.00 3100000.00 2900000.00
    15 Total Non-Current Assets 3031402000 3495636000 2402789000 897051000 1065247000 1091722000 788168000 730465000 1169703000 873026000 668407000 648462000 112898000 104626000 150173000 163943000 138741000 130605000 159148000 149039000 369695000 37200000 17600000 14000000
    16 Other Assets 587027000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    17 Total Assets 11751808000 8318465000 6245898000 3546014000 2896787000 2498875000 2334679000 2319041000 2759288000 2204280000 1725446000 1955488000 980479000 601477000 921579000 548998000 545453000 724411000 815720000 925131000 772881000 232400000 266300000 295600000
    18 Accounts Payables 155139000.00 87610000.00 110987000.00 73994000.00 61451000.00 74942000.00 71194000.00 49327000.00 101292000.00 74642000.00 35851000.00 36989000.00 51760000.00 32750000.00 15368000.00 6210000.00 6660000.00 12306000.00 16745000.00 11628000.00 3847000.00 3000000.00 2800000.00 4200000.00
    19 S-T Debt 0.00 0.00 0.00 0.00 300000000.00 71478000.00 14206000.00 0.00 0.00 0.00 136991000.00 0.00 0.00 19997000.00 103758000.00 0.00 0.00 4660000.00 2195000.00 4579000.00 2377000.00 2400000.00 2800000.00 2500000.00
    20 Income Tax Payables 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    21 Deferred Revenue 0.00 0.00 0.00 237570000.00 79421000.00 16296000.00 17468000.00 21510000.00 27566000.00 45037000.00 74619000.00 74956000.00 37678000.00 25528000.00 33889000.00 31449000.00 47741000.00 7746000.00 11888000.00 39498000.00 0.00 0.00 0.00 0.00
    22 Other Current Liabilities 1722394000.00 130305000.00 40589000.00 27029000.00 10943000.00 12802000.00 782000.00 8084000.00 19702000.00 405616000.00 83949000.00 15227000.00 21255000.00 27151000.00 4635000.00 2988000.00 4688000.00 14000000.00 0.00 0.00 32447000.00 13100000.00 7500000.00 7000000.00
    23 Total Current Liabilities 1877533000.00 1334827000.00 1120292000.00 807260000.00 792537000.00 506349000.00 368254000.00 397829000.00 432624000.00 392348000.00 474783000.00 284883000.00 216564000.00 199279000.00 251014000.00 100243000.00 153745000.00 139067000.00 64597000.00 91553000.00 38671000.00 18500000.00 13100000.00 13700000.00
    24 L-T Debt 0.00 0.00 0.00 0.00 296998000.00 223969000.00 280569000.00 0.00 400000000.00 400000000.00 400000000.00 121765000.00 287500000.00 0.00 19997000.00 180097000.00 334997000.00 315000000.00 315000000.00 315000000.00 347313000.00 4700000.00 7000000.00 5900000.00
  • Line Item (in $M) FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998 FY 1997
    1 Net Income (Earnings) 2711647000 1176810000 2096896000 263484000 -112052000 -556334000 -738555000 -445028000 -107032000 29574000 -754626000 -642178000 -459851000 -391279000 -206891000 -203417000 -166247000 -196767000 -108621000 -66233000 -39658000 -41000000 -33100000 -19800000
    2 D&A 109515000.00 106941000.00 72420000.00 61397000.00 61398000.00 62343000.00 63257000.00 48365000.00 38191000.00 35041000.00 30459000.00 30107000.00 32196000.00 27459000.00 25868000.00 27289000.00 29640000.00 23438000.00 25432000.00 17964000.00 9095000.00 6300000.00 4500000.00 3600000.00
    3 Deferred Income Tax 277341000.00 167387000.00 -1512325000.00 -120513000.00 16961000.00 3283000.00 281000.00 -285053000.00 36660000.00 -7501000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    4 Stock-Based Compensation (SBC) 429461000.00 360489000.00 325047000.00 290736000.00 237705000.00 231025000.00 177542000.00 127303000.00 114285000.00 126751000.00 97676000.00 86722000.00 63012000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    5 Change in Working Capital 2767844000.00 765185000.00 881114000.00 802700000.00 138199000.00 -277453000.00 -12490000.00 33786000.00 218055000.00 356650000.00 -439887000.00 371126000.00 353445000.00 -222820000.00 235580000.00 31845000.00 -201772000.00 -137236000.00 -92564000.00 320024000.00 187815000.00 -58900000.00 -32300000.00 142800000.00
    6 Accounts Receivables -223444000.00 -225587000.00 -108152000.00 -71759000.00 -33027000.00 -104847000.00 7428000.00 53363000.00 39912000.00 -170606000.00 -2923000.00 13900000.00 7831000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    7 Inventory -132014000.00 -64047000.00 -31965000.00 -44984000.00 -16450000.00 -23146000.00 -16469000.00 7142000.00 -29925000.00 -111388000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    8 Accounts Payables 51276000.00 -22785000.00 36554000.00 8753000.00 -11745000.00 -1709000.00 25048000.00 -49234000.00 14892000.00 37468000.00 -1182000.00 -15057000.00 19010000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    9 Other Working Capital 6255846000 3488002000 2722817000 1841703000 1039003000 900804000 1178257000 1190747000 1156961000 938906000 582256000 1022143000 651017000 297572000 520392000 284812000 252967000 454739000 591975000 684539000 364515000 176700000 235600000 267900000
    10 Other Non-Cash Items 0.00 21401000.00 12089000.00 157196000.00 6140000.00 9532000.00 0.00 20196000.00 10049000.00 264000.00 -31000.00 5666000.00 0.00 63747000.00 46583000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -100000.00 -100000.00
    11 Net Cash Provided by Operating Activities 3253505000.00 1569330000.00 1270286000.00 844942000.00 236103000.00 -365432000.00 -513199000.00 -51570000.00 267841000.00 143735000.00 -635442000.00 -427586000.00 -226482000.00 -252476000.00 -22475000.00 -172054000.00 -142160000.00 -167623000.00 -79539000.00 -8074000.00 -16644000.00 -31800000.00 -31100000.00 -9400000.00
    12 Investments in PP&E -259798000.00 -75451000.00 -95524000.00 -99421000.00 -56563000.00 -45302000.00 -51201000.00 -51393000.00 -71140000.00 -34595000.00 -38054000.00 -23496000.00 -32180000.00 -32415000.00 -32417000.00 -16959000.00 -12495000.00 -17351000.00 -41219000.00 -53899000.00 -11913000.00 -16200000.00 -7900000.00 -6000000.00
    13 Acquisitions (Net) 0.00 -1154000000.00 0.00 0.00 0.00 -80000000.00 -10000000.00 0.00 0.00 -60000000.00 0.00 -87000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    14 Purchase of Investments -431396000 -576515000 -530389000 -532581000 -649700000 -663041000 -1424172000 -2412418000 -1705829000 -721545000 -1234719000 -1186701000 -755422000 -318039000 -508085000 -236489000 -148506000 -555842000 -702986000 -1252781000 -1312765000 -366000000 -507500000 -303600000
    15 Sales/Maturities of Investments 372342000 570860000 431576000 369214000 757562000 1067443000 1557938000 2348295000 1367927000 1016040000 1284806000 788263000 427648000 755620000 302438000 243410000 292351000 593998000 728037000 1176186000 1088582000 428900000 495300000 191000000
    16 Other Investing Activities 0.00 0.00 -7821000.00 -14893000.00 53170000.00 -10244000.00 1394000.00 61386000.00 -16775000.00 12512000.00 -4732000.00 624000.00 -696000.00 0.00 29593000.00 8306000.00 -23922000.00 1633000.00 200000.00 0.00 -233000.00 -10300000.00 -300000.00 -200000.00
    17 Net Cash used for Investing Activities 99388000.00 -1235318000.00 -202158000.00 -437681000.00 104469000.00 268856000.00 73959000.00 -54130000.00 -425817000.00 212412000.00 7301000.00 -508732000.00 -360650000.00 405166000.00 -208471000.00 -1732000.00 107428000.00 22438000.00 -15962000.00 -130494000.00 -236329000.00 36400000.00 -20400000.00 -118800000.00
    18 Debt Repayment -42275000.00 -39185000.00 -33388000.00 -319336000.00 -93029000.00 -20335000.00 -81692000.00 -83742000.00 -21488000.00 -250000000.00 -22000.00 -131000.00 -19997000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    19 Common Stock Issued 264946000.00 343244000.00 289293000.00 344840000.00 68230000.00 185592000.00 274615000.00 265878000.00 191721000.00 124862000.00 33434000.00 849235000.00 362128000.00 31965000.00 366035000.00 0.00 8742000.00 11959000.00 13327000.00 19653000.00 42438000.00 5500000.00 2800000.00 164900000.00
    20 Common Stock Repurchased -539136000.00 -192015000.00 -350043000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    21 Dividends Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
    22 Other Financing Activities 0.00 4683000.00 2079000.00 8234000.00 71897000.00 0.00 2160000.00 -1252000.00 1971000.00 900000.00 0.00 0.00 0.00 -53000.00 -170000.00 -135000.00 -4805000.00 0.00 0.00 0.00 0.00 0.00 0.00 1200000.00
    23 Net Cash Used Provided by Financing Activities -505281000.00 126773000.00 -71219000.00 68404000.00 133271000.00 188919000.00 497376000.00 180884000.00 172204000.00 -124238000.00 425057000.00 999006000.00 620738000.00 -10190000.00 365865000.00 197456000.00 -8626000.00 37468000.00 13842000.00 -3982000.00 544031000.00 2800000.00 4200000.00 164800000.00
    24 Net Change in Cash 2868164000.00 462428000.00 990727000.00 481467000.00 469177000.00 89509000.00 55960000.00 79892000.00 14087000.00 232123000.00 -203461000.00 57543000.00 33452000.00 142492000.00 135126000.00 23039000.00 -43153000.00 -9939000.00 -81107000.00 -157454000.00 290542000.00 7300000.00 0.00 0.00
  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 7/24/1991
    Stonk Exchange: NASDAQ
    • Vertex Pharmaceuticals, Inc
    • engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,500 full-time employees.
    • The firm is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
    • The firm's marketed medicines are ORKAMBI and KALYDECO.
    • ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene.
    • KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene.
    • The firm's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371.
    • VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.



Looking for a specific stock? Please use our search ("TSLA, AAPL, SPY...") at the top. Otherwise, you can refer to the lists below.
List of all stocks by first letter/number.